sulfated oxysterol
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 22, 2018 (NCT03394781)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
SREBF1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04447404 | Phase 2 | Sep 21, 2020 | CTI BioPharma, Durect |
| NCT03432260 | Phase 2 | Apr 18, 2018 | CTI BioPharma, Durect |
| NCT03394781 | Phase 2 | Jan 22, 2018 | Durect, inVentiv |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Durect | For profit | 3 | 3 | 1 | 2018 |
| CTI BioPharma | For profit | 2 | 0 | 1 | 2018 |
| inVentiv | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1